Indium (In-111) Oxinate (Indium (111in) Oxine)

The oxine complex is lipophilic, allowing it to cross cell membranes. Inside the cell, the indium‑111 ion binds to intracellular proteins, becoming trapped. The radionuclide emits gamma photons that are detected by a SPECT scanner, producing images that highlight the distribution of the labeled cells or antibodies.

The administered activity is determined by the prescribing physician based on the specific diagnostic protocol, patient weight, and the intended imaging target. Dosing is individualized and follows regulatory guidelines for radiopharmaceuticals.

Safety in pregnancy and lactation has not been fully established. Use is generally reserved for situations where the diagnostic benefit outweighs potential radiation risk to the fetus. Breastfeeding mothers should discuss risk assessment with their clinician, who may advise temporary cessation of nursing.

Enquiries are submitted via the product page on gnhindia.com, where you specify the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain where required) and any necessary import documentation.

Compared with technetium‑99m labeled agents, Indium‑111 provides longer half‑life and higher energy gamma emissions, allowing delayed imaging and better visualization of slow‑accumulating targets such as labeled leukocytes. However, it delivers a higher radiation dose, so selection depends on clinical need and imaging schedule.

The product must be stored refrigerated at 2‑8 °C, protected from light, and never frozen or shaken. It should be kept in its original container until use, and handled by trained personnel using appropriate radiation safety measures.

Indium (In-111) Oxinate is administered intravenously by a qualified healthcare professional. The preparation is injected as a sterile solution, and the patient is monitored for any immediate adverse reactions during and after the administration.

Serious risks include severe allergic reactions (anaphylaxis), significant hypotension, radiation‑induced bone marrow suppression, and rare organ toxicity. Prompt recognition and management of these events are essential, and patients are observed after injection for any signs of adverse effects.

Patients with a known hypersensitivity to indium compounds, those who are pregnant unless the diagnostic benefit justifies the risk, and individuals with severe uncontrolled cardiac or respiratory conditions should avoid this agent. The prescribing clinician must evaluate each case individually.